CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on harnessing the potential of hypoxia-inducible factor (HIF)
biology to develop and commercialize novel therapeutics to treat kidney
disease and other serious diseases, today announced that it was added to
the Russell 3000®,Russell 2000®, and
Russell Global Indexes when the Russell Investment Group reconstituted
its family of U.S. indexes after the stock market close on June 27, 2014.
Annual reconstitution of Russell's U.S. indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total market
capitalization. Membership in the Russell 3000®, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell 2000®
Index as well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes. The Russell 3000®
also serves as the U.S. component to the Russell Global Index, which
Russell launched in 2007.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Approximately $5.2 trillion in assets are
benchmarked to the Russell Indexes.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on harnessing the potential of
hypoxia-inducible factor (HIF) biology to develop and commercialize
novel, proprietary therapeutics to treat kidney disease and other
serious diseases. Akebia's lead clinical compound, AKB-6548, is a
once-daily, oral therapy currently in Phase 2b clinical development for
the treatment of anemia related to chronic kidney disease, a serious
medical condition that leads to increased morbidity and mortality if
left untreated. For more information on Akebia, please visit www.akebia.com.
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects. The words "anticipate," "appear," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project,"
"target," "potential," "will," "would," "could," "should," "continue,"
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement, including the risks
and uncertainties identified under the heading "Risk Factors" in
Akebia's Quarterly Report on Form 10-Q for the quarter ended March 31,
2014, and other filings that Akebia may make with the Securities and
Exchange Commission in the future. Akebia does not undertake, and
specifically disclaims, any obligation to update any forward-looking
statements contained in this press release.
Investors:
Argot Partners, LLC
David Pitts,
+1-212-600-1902
david@argotpartners.com
or
Susan
Kim, +1-212-203-4433
susan@argotpartners.com
or
Media:
Feinstein
Kean Healthcare
Liz Falcone, +1-617-761-6727
liz.falcone@fkhealth.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media